TVTX Travere Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1438533 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY49.4%
TTM net income YoY-37.2%
TTM EPS YoY-26.2%
Revenue 3-yr CAGR71.3%
Net income 3-yr CAGR—
Margins
Gross margin98.5%
Operating margin-20.5%
Net margin-18.7%
FCF margin—
EBITDA margin-12.4%
Returns
ROE-252.7%
ROA-17.5%
ROIC (approx.)—
Asset turnover0.94x
Leverage & solvency
Liabilities / assets97.3%
Debt / equity0.00x
Current ratio3.00x
Interest coverage-15.05x
Cash quality & payout
Operating cash flow / net income-1.54x
Accruals ratio-44.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $490.73M | $233.18M | $145.24M | $109.46M | $131.84M |
| Cost of revenue | $10.34M | $7.74M | $11.45M | $4.42M | $3.82M |
| Gross profit | $480.39M | $225.43M | $133.79M | $105.04M | $128.02M |
| R&D expense | $206.01M | $217.50M | $244.99M | $227.33M | $201.16M |
| SG&A expense | $337.20M | $264.12M | $265.54M | $197.52M | $126.28M |
| Operating income | -$62.82M | -$323.83M | -$388.14M | -$319.81M | -$199.43M |
| Interest expense | $10.75M | $11.18M | $11.33M | $11.01M | $19.70M |
| Pretax income | -$49.27M | -$320.51M | -$376.11M | -$331.15M | -$216.88M |
| Income tax | $988,000 | $120,000 | $223,000 | $313,000 | $409,000 |
| Net income | -$25.55M | -$321.55M | -$111.40M | -$278.48M | -$180.09M |
| EBITDA | -$2.08M | -$280.27M | -$349.61M | -$299.09M | -$186.68M |
| EPS (basic) | -0.29 | -4.08 | -1.50 | -4.37 | -3.01 |
| EPS (diluted) | -0.29 | -4.08 | -1.50 | -4.37 | -3.01 |
| Weighted avg. shares (diluted) | 89.21M | 78.89M | 74.27M | 63.76M | 59.83M |
| Balance sheet | |||||
| Cash & equivalents | $93.03M | $58.53M | $58.18M | $61.69M | $165.75M |
| Short-term investments | $145.38M | — | $248.64M | $285.53M | $262.19M |
| Receivables | $80.13M | $27.12M | $21.18M | $16.65M | $15.91M |
| Inventory | $36.16M | $41.86M | $9.41M | $4.52M | $7.31M |
| Current assets | $437.56M | $416.70M | $616.77M | $486.44M | $582.83M |
| PP&E, net | $4.02M | $5.34M | $7.48M | $9.05M | $11.11M |
| Goodwill | — | $800,000 | $800,000 | $800,000 | $900,000 |
| Intangibles | $113.87M | $103.97M | $104.44M | $97.07M | $148.44M |
| Total assets | $605.19M | $594.12M | $788.91M | $672.59M | $776.63M |
| Current liabilities | $159.90M | $200.75M | $177.91M | $142.16M | $124.09M |
| Total liabilities | $490.36M | $535.05M | $588.10M | $629.73M | $474.52M |
| Shareholders' equity | $114.83M | $59.08M | $200.81M | $42.85M | $302.11M |
| Shares outstanding | 90.92M | 87.45M | 75.37M | 64.29M | 62.49M |
| Cash flow statement | |||||
| Operating cash flow | $37.78M | -$237.47M | -$280.02M | -$186.29M | -$14.79M |
| Capital expenditure | — | — | $668,000 | $191,000 | $5.10M |
| Free cash flow | — | — | -$280.69M | -$186.48M | -$19.89M |
| Investing cash flow | $27.89M | $99.33M | $55.78M | -$32.55M | -$137.62M |
| Financing cash flow | -$33.47M | $139.42M | $218.75M | $117.57M | $231.68M |
| Depreciation & amortization | $60.74M | $43.55M | $38.53M | $20.72M | $12.75M |
| Stock-based compensation | $44.87M | $36.91M | $44.25M | $38.14M | $29.57M |
Free plan shows the latest 5 periods; Pro shows all 16 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.